Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

"The NMPA approval of vebreltinib is an important milestone toward providing a new treatment option for patients with MET exon 14 skipping NSCLC in China. ...

November 17, 2023 | Friday | News
SciSparc Celebrates Major Breakthrough with Positive Results Demonstrating Remarkable Impact on Alzheimer's Agitation in Treatment

SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central...

November 16, 2023 | Thursday | News
Global Coalition and Cure Brain Cancer Foundation Open Glioblastoma Trial in Australia

GBM AGILE Adaptive Platform Trial Recruiting in Australia Austin Health in Melbourne and Royal North Shore Hospital in Sydney are Now Enrolling Patients ...

November 15, 2023 | Wednesday | News
FDA Clears Solid Biosciences' Gene Therapy for Duchenne Muscular Dystrophy

Planning to initiate Phase 1/2 trial in pediatric DMD Patients – – First cohort to study patients 4 to < 6 years of age –   &l...

November 15, 2023 | Wednesday | News
Hepion Pharmaceuticals Reports Significant Liver Stiffness Reduction in Advanced MASH Liver Disease Study

Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease bioma...

November 14, 2023 | Tuesday | News
Bio-Botanica®'s Puresterol® Serums Show Wrinkle Reduction in Clinical Trials

Pueraria mirifica grows only in the rich soils of the high-altitude rainforests of Thailand and has been used by the Thais for a millennium as a rejuvenato...

November 10, 2023 | Friday | News
BioPhy Launches Breakthrough AI Platform to Accelerate the Trillion Dollar Drug Development Market

BioPhy  launched its AI operating system that radically accelerates the identification and development of the most promising drug candidates. By combi...

November 08, 2023 | Wednesday | News
AdvanCell Initiates Phase I/II TheraPb Trial for Metastatic Prostate Cancer with 212Pb-ADVC001

“The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, ...

November 08, 2023 | Wednesday | News
Cellares and Cabaletta Bio Join Forces for Automated Manufacturing of CABA-201 on Cell Shuttle Platform

-Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, an...

November 07, 2023 | Tuesday | News
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease

1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia. Top-line results for on-going, 52-week...

November 07, 2023 | Tuesday | News
Senti Bio Collaborates with Celest Therapeutics to Advance SENTI-301A in China

– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 202...

November 07, 2023 | Tuesday | News
Boehringer Ingelheim Hits Milestone in CKD: Promising Phase II Results with Aldosterone Synthase Inhibitor + Empagliflozin

Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibi...

November 06, 2023 | Monday | News
MoonLake Immunotherapeutics Reveals Breakthrough Phase 2 Results for Nanobody® Sonelokimab in Psoriatic Arthritis

First placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody® to report positive topline results in support of pote...

November 06, 2023 | Monday | News
Pfizer Advances GLP-1 Receptor Agonist PF-06954522 to Phase 1 Trial with Sosei Heptares Collaboration

Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) has been notified by Pfizer that it has entered a new oral s...

November 06, 2023 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close